Vico Therapeutics
5 known investors
Vico Therapeutics is a genetic medicine company developing antisense oligonucleotide (ASO) therapies that target the CAG repeat expansion mutation underlying polyglutamine diseases such as Huntington's disease and spinocerebellar ataxias. Its lead clinical candidate, VO659, uses an allele-preferential approach to reduce disease-causing mutations while preserving normal gene function.
AI & Machine LearningBiotechHealthtech
Investors · 5
In the news
Frequently asked questions
- What does Vico Therapeutics do?
- Vico Therapeutics is a genetic medicine company developing antisense oligonucleotide (ASO) therapies that target the CAG repeat expansion mutation underlying polyglutamine diseases such as Huntington's disease and spinocerebellar ataxias. Its lead clinical candidate, VO659, uses an allele-preferential approach to reduce disease-causing mutations while preserving normal gene function.
- Who are Vico Therapeutics's investors?
- Vico Therapeutics's investors include Droia Ventures, Kurma Partners, Pureos Bioventures, Seroba Life Sciences, Idinvest Partners.